KETANSERIN

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H22FN3O3
Molecular Weight	395.4268
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC1=CC=C(C=C1)C(=O)C2CCN(CCN3C(=O)NC4=C(C=CC=C4)C3=O)CC2

InChI

InChIKey=FPCCSQOGAWCVBH-UHFFFAOYSA-N

InChI=1S/C22H22FN3O3/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)

HIDE SMILES / InChI

Molecular Formula	C22H22FN3O3
Molecular Weight	395.4268
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17147663

Ketanserin is a selective 5HT2A receptor antagonist which was initially developed as an anti-hypertensive medicine. However, now the drug is available as a topical gel formulation for the treatment of wounds, burns, ulcers and anal fissure (Sufrexal brand name). The drug action is explained by its ability to accelerate epithelialization.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 2a (5-HT2a) receptor 237 Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12569067	Antagonist 2849		2.7 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Skin ulcer 8 Sources: http://www.medicatione.com/?c=drug&s=sufrexal%20p&ingredient=benzocaine/ketanserin	Curative	Approved 8583	Sufrexal Approved Use Non-neoplastic dermal and uterine cervix ulcers. Traumatic wounds such as decubitus ulcers. Preparation of tissue for grafting and flaps. Uninfected burns. Regeneration of the uterine cervix. Anal fissure
Cervix ulcer 2 Sources: http://www.medicatione.com/?c=drug&s=sufrexal%20p&ingredient=benzocaine/ketanserin	Curative	Approved 8583	Sufrexal Approved Use Non-neoplastic dermal and uterine cervix ulcers. Traumatic wounds such as decubitus ulcers. Preparation of tissue for grafting and flaps. Uninfected burns. Regeneration of the uterine cervix. Anal fissure
Traumatic wounds 2 Sources: http://www.medicatione.com/?c=drug&s=sufrexal%20p&ingredient=benzocaine/ketanserin	Curative	Approved 8583	Sufrexal Approved Use Non-neoplastic dermal and uterine cervix ulcers. Traumatic wounds such as decubitus ulcers. Preparation of tissue for grafting and flaps. Uninfected burns. Regeneration of the uterine cervix. Anal fissure
Burn 40 Sources: http://www.medicatione.com/?c=drug&s=sufrexal%20p&ingredient=benzocaine/ketanserin	Curative	Approved 8583	Sufrexal Approved Use Non-neoplastic dermal and uterine cervix ulcers. Traumatic wounds such as decubitus ulcers. Preparation of tissue for grafting and flaps. Uninfected burns. Regeneration of the uterine cervix. Anal fissure
Anal fissure 6 Sources: http://www.medicatione.com/?c=drug&s=sufrexal%20p&ingredient=benzocaine/ketanserin	Curative	Approved 8583	Sufrexal Approved Use Non-neoplastic dermal and uterine cervix ulcers. Traumatic wounds such as decubitus ulcers. Preparation of tissue for grafting and flaps. Uninfected burns. Regeneration of the uterine cervix. Anal fissure

C_max

Value	Dose	Analyte	Population
193 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6617728/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
110.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6196551/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
127 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
60.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
46.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/	40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	KETANSERIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
14.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/	20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	KETANSERIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
71.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
198 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
287 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
385.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6196551/	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
392.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6196551/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
632 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
637 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
855 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/	40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	KETANSERIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
265 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/	20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	KETANSERIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
279 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
625 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
992 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
12.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6617728/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6617728/	0.15 mg/kg bw single, intravenous dose: 0.15 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
15.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6196551/	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
18.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6196551/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
29 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
28 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
40 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/	40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	KETANSERIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
39 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/	20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	KETANSERIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
16.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
16.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3792432/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Analyte	Population
6.1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6617728/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6617728/	0.15 mg/kg bw single, intravenous dose: 0.15 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
9.36% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6196551/	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	KETANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2378791/		KETANSERIN plasma	Homo sapiens

Doses

Dose	Population	Adverse events
10 mg single, intraarterial Highest studied dose Dose: 10 mg Route: intraarterial Route: single Dose: 10 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2840293/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2840293/	Sources: https://pubmed.ncbi.nlm.nih.gov/2840293/
10 mg single, intravenous Highest studied dose Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6812750/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6812750/	Other AEs: Sedation, Dizziness... Other AEs: Sedation (44%) Dizziness (44%) Sources: https://pubmed.ncbi.nlm.nih.gov/6812750/
60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6353879/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6353879/	Disc. AE: Fainting, Dizziness... AEs leading to discontinuation/dose reduction: Fainting (10%) Dizziness (10%) Fall (20%) Sources: https://pubmed.ncbi.nlm.nih.gov/6353879/

AEs

AE	Significance	Dose	Population
Dizziness	44%	10 mg single, intravenous Highest studied dose Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6812750/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6812750/
Sedation	44%	10 mg single, intravenous Highest studied dose Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6812750/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6812750/
Dizziness	10% Disc. AE	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6353879/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6353879/
Fainting	10% Disc. AE	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6353879/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6353879/
Fall	20% Disc. AE	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6353879/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6353879/

PubMed

Title	Date	PubMed
Serotonin(2) receptors mediate respiratory recovery after cervical spinal cord hemisection in adult rats.	2001-12	11717232
Influence of serotonin on the glutamate-induced excitations of secondary vestibular neurons in the rat.	2001-12	11716569
Inhibitory presynaptic 5-hydroxytryptamine(2A) receptors regulate evoked glutamate release from rat cerebellar mossy fibers.	2001-12	11714900
Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemic-atherosclerotic canine coronary arteries.	2001-11-06	11696474
Antidepressant-like effects of aniracetam in aged rats and its mode of action.	2001-11	11702095
Expression of serotonin 5-HT(2A) receptors in the human cerebellum and alterations in schizophrenia.	2001-11	11574947
Ketanserin attenuates the behavioural effects of corticosterone: implications for 5-HT(2A) receptor regulation.	2001-10-05	11675041
Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [(3)H]GR 125743.	2001-10-05	11578619
Use of topical ketanserin for the treatment of ulcers in leprosy patients.	2001-10-03	11579646
Binding affinity of a newly synthesized 5-HT2 antagonist, AT-1015 (N-[2-[4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-piperidino]ethyl]-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate), in the rabbit platelet membrane.	2001-10	11642330
Enhanced contraction to 5-hydroxytryptamine is not due to "unmasking" of 5-hydroxytryptamine(1b) receptors in the mesenteric artery of the deoxycorticosterone acetate-salt rat.	2001-10	11641304
Physiology and pathophysiology of the serotonergic system and its implications on mental and physical performance. Part II.	2001-10	11590475
Activation of Erk mitogen-activated protein kinase proteins by vascular serotonin receptors.	2001-10	11588524
Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists.	2001-10	11562430
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.	2001-10	11561066
Neuroepithelial bodies in mammalian lung express functional serotonin type 3 receptor.	2001-10	11557597
Effects of 5-HT(2) receptor antagonists on the anti-immobility effects of imipramine in the forced swimming test with mice.	2001-09-21	11567652
Stimulation of 5-HT2 receptors in the nucleus tractus solitarius enhances NMDA receptor-mediated reflex-evoked bradycardiac responses in the rat.	2001-09-17	11570703
Prostaglandins may participate in opioidergic and cholinergic control of the diurnal changes of tuberoinfundibular dopaminergic neuronal activity and serum prolactin level in ovariectomized, estrogen-treated rats.	2001-09-01	11604250
Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons.	2001-09-01	11517239
On the role of serotonin2A/2C receptors in the sensitization to cocaine.	2001-09	11596864
Role of 5-HT(2) receptor subtypes in depletion of 5-HT induced by p-chloroamphetamine in the mouse frontal cortex.	2001-08-24	11511381
Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists.	2001-08-18	11509227
The effects of hypothyroidism on 5-HT1A and 5-HT2A receptors and the serotonin transporter protein in the rat brain.	2001-08-18	11508497
Serotonin 2A receptor regulation of striatal neuropeptide gene expression is selective for tachykinin, but not enkephalin neurons following dopamine depletion.	2001-08-15	11483243
Activation of spinal serotonin(2A/2C) receptors augments nociceptive responses in the rat.	2001-08-10	11489268
Blockade of D1 dopamine receptors in the ventral tegmental area decreases cocaine reward: possible role for dendritically released dopamine.	2001-08-01	11466456
Catecholamines inhibit lipid peroxidation in young, aged, and Alzheimer's disease brain.	2001-08-01	11461768
Disturbance of serotonin 5HT2 receptors in remitted patients suffering from hereditary depressive disorder.	2001-08	11556203
In vivo evaluation of 4-[123I]iodo-N-[2[4-(6-trifluoromethyl-2-pyridinyl)-1-piperazinyl]ethyl]benzamide, a potential SPECT radioligand for the 5-HT1A receptor.	2001-08	11518645
Complex interaction of ergovaline with 5-HT2A, 5-HT1B/1D, and alpha1 receptors in isolated arteries of rat and guinea pig.	2001-08	11518230
Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors.	2001-08	11489456
5-HT1A receptor-mediated activation of G-protein-gated inwardly rectifying K+ current in rat periaqueductal gray neurons.	2001-08	11489454
Chronic intermittent hypoxia elicits serotonin-dependent plasticity in the central neural control of breathing.	2001-07-15	11438615
Effects of 5-HT2 and 5-HT3 receptors on the modulation of nociceptive transmission in rat spinal cord according to the formalin test.	2001-07-13	11470259
Blood pressure patterns in pregnant patients on oral ketanserin.	2001-07-12	11447496
Researching the antidepressant actions of Hypericum perforatum (St. John's wort) in animals and man.	2001-07	11518072
Synthesis and 5-HT2A antagonist activity of derivatives of the novel heterocycles indolo[3,2-d]pyrrolo[3,2-g]azecine and benzo[d]pyrrolo[3,2-g]azecine compared to the benz[d]indolo[2,3-g]azecine derivative LE 300.	2001-07	11512275
Altered serotonin 2A receptor activity in women who have recovered from bulimia nervosa.	2001-07	11431241
Pharmacological evaluation of (+)-2- [123I]A-69024: a radioligand for in vivo studies of dopamine D1 receptors.	2001-06-29	11476188
Role of prostanoids and endothelins in the prevention of cyclosporine-induced nephrotoxicity.	2001-06-22	11418017
Platelet 3H ketanserin binding in migraine.	2001-06	11472383
Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.	2001-06	11459121
Different receptor subtypes are involved in the serotonin-induced modulation of epileptiform activity in rat frontal cortex in vitro.	2001-06	11453105
The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution.	2001-06	11414657
Characterisation of agonist binding on human 5-HT2C receptor isoforms.	2001-05-11	11426831
Do mucosal mast cells contribute to the immediate asthma response?	2001-05	11430471
Effect of fluvoxamine and N-methyl-D-aspartate receptor antagonists on shock-induced depression in mice.	2001-04	11480226
Relaxation induced by serotonin and sumatriptan in isolated guinea pig gallbladder strips.	2001-03	11426669
Gastroprokinetic effect and mechanism of SK-896, a new motilin analogue, during the interdigestive period in conscious dogs.	2001	11490202

Patents

Sample Use Guides

In Vivo Use Guide

Apply a thin layer twice a day (topical gel) or use one applicator every 24 hours at night before bed for two weeks (vaginal application). In case of anal fissure, apply a small amount of the gel digitally in the anus area 3 times a day, preferably after bowel movement and cleaning the area with soap and water. The minimum recommended treatment time is 15 days.

Route of Administration: Topical

In Vitro Use Guide

2% and 20% topical ketanserin significantly accelerates both the vascular epithelial rates of wound healing in full-thickness nonpathologic skin wounds.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:48:17 GMT 2025` Edited by `admin` on `Wed Apr 02 09:48:17 GMT 2025`
Record UNII	97F9DE4CT4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

KETANSERIN

Official Name

English

R-41,468

Preferred Name

English

KETANSERIN [USAN]

Common Name

English

ketanserin [INN]

Common Name

English

3-(2-(4-(P-FLUOROBENZOYL)PIPERIDINO)ETHYL)-2,4-(1H,3H)-QUINAZOLINEDIONE

Common Name

English

KETANSERIN [MART.]

Common Name

English

2,4(1H,3H)-QUINAZOLINEDIONE, 3-(2-(4-(4-FLUOROBENZOYL)-1-PIPERIDINYL)ETHYL)-

Systematic Name

English

Ketanserin [WHO-DD]

Common Name

English

KETANSERIN [MI]

Common Name

English

R-41468

Code

English

Classification Tree Code System Code

WHO-VATC

QD03AX90